Recent Advances

Modeling Neurofibromas Using Human Induced Pluripotent Stem Cells and Genetically Engineered Mice

Juan Mo, Corina Anastasaki, et al., The Journal of Clinical Investigation

Neurofibromatosis type 1 (NF1) is a common tumor predisposition syndrome caused by NF1 gene mutation, in which affected individuals develop Schwann cell lineage peripheral nerve sheath tumors (neurofibromas). To investigate human neurofibroma pathogenesis, the Gutmann laboratory in collaboration with Dr. Lu Le (University of Texas, Southwestern) differentiated a series of isogenic, patient-specific NF1-mutant human induced pluripotent stem cells (hiPSCs) into Schwannian lineage cells (SLCs). We found that, although control and heterozygous NF1-mutant hiPSCs-SLCs did not form tumors following mouse sciatic nerve implantation, NF1-null SLCs formed bona fide neurofibromas with high levels of SOX10 expression. To confirm that SOX10+ SLCs contained the cells of origin for neurofibromas, both Nf1 genes were inactivated in mouse Sox10+ cells, leading to classic nodular cutaneous and plexiform neurofibroma formation that completely recapitulated their human counterparts. Moreover, we discovered that NF1 loss impaired Schwann cell differentiation by inducing a persistent stem-like state to expand the pool of progenitors required to initiate tumor formation, indicating that, in addition to regulating MAPK-mediated cell growth, NF1 loss also altered Schwann cell differentiation to promote neurofibroma development. Taken together, our laboratories collectively established a complementary humanized neurofibroma explant and, to our knowledge, first-in-kind genetically engineered nodular cutaneous neurofibroma mouse models that delineate neurofibroma pathogenesis amenable to future therapeutic target discovery and evaluation.

Juan Mo, PhD

Corina Anastasaki, PhD

Neurons Activate T Cells to Create a Supportive Microenvironment for Brain Tumor Formation and Growth

Defining the neuroimmune-cancer cell axis

Xiaofan Guo, Yuan Pan, et al., Nature Communications

For the past 25 years, my laboratory has developed and employed genetically engineered mice to understand why brain tumors form in children with the Neurofibromatosis type 1 (NF1) cancer predisposition syndrome(1). Using these authenticated preclinical mouse models of NF1-associated optic gliomas (low-grade astrocytomas of the optic nerves)(2), we showed that microglia, macrophage-like cells in the brain, produce growth factors necessary for tumor development, proliferation, and vision loss(3, 4, 5, 6). However, it was not clear how microglia get activated to control tumor pathogenesis.

This all changed thanks to Reviewer #3.

To create a transplantable low-grade glioma model, Dr. Yi-Hsien Chen, a postdoctoral fellow in our group, isolated cancer stem cells from Nf1 optic glioma mice, and showed that they could form tumors when injected into the brains of naïve immunocompetent mice(7). We were very excited about this finding, and submitted the paper for review. We were surprised that one of the reviewers insisted that we repeat these experiments using immunocompromised mice, similar to what other investigators have historically employed for human brain tumor xenograft studies. At first blush, this seemed like a strange request, as we had already demonstrated tumor formation in mice with a normal immune system. To our amazement, when Yi-Hsien injected these optic glioma stem cells into athymic mice lacking functional T cells, no tumors were observed!

The finding that T cells were required for brain tumor formation was exciting, and prompted another postdoctoral fellow, Dr. Yuan Pan, to confirm and extend these observations. Yuan went on to demonstrate that the inability of athymic mice to support optic glioma formation resulted from impaired microglia function, including reduced expression of Ccr2 and Ccl5, both of which are required for Nf1 optic glioma growth. She further demonstrated that reduced Ccr2 and Ccl5 expression by athymic microglia could be restored by soluble factors produced by activated T cells(8).

While these studies established a critical role for T cells in microglia-mediated glioma formation and growth, how T cells became activated and how they created a supportive tumor microenvironment remained unknown. Enter Dr. Xiaofan (Gary) Guo, a graduate student in our laboratory who had previously shown that T cells and microglia are drawn into the tumor microenvironment by chemokines secreted from the glioma cells themselves(9). In our latest report(10), Gary and his colleagues nicely demonstrated that T cell entry into the brain is required for optic glioma growth, and that, upon activation, T cells produce Ccl4, which in turn induces microglia to secrete Ccl5, the growth factor necessary for optic glioma growth(11). Moreover, Gary discovered that neurons were the cells responsible for activating T cells, thus establishing a neuroimmune-cancer cell circuit.

We are very excited about these findings, as they have important implications for the field.

First, the fact that nerve cells are active participants in brain tumor development and growth adds to our growing appreciation of the role of neurons in cancer – ushering in the new field of Cancer Neuroscience(12). Researchers in our team are now investigating the role of neurons in dictating human and mouse nervous system tumor formation and progression. Second, our studies demonstrate that T cells are key regulators of the brain tumor microenvironment, prompting us to explore the idea that T cells can alter microglia function in the brain, both in health and in the setting of central nervous system disease(13). Third, since we showed that T cells are recruited into the optic nerve (brain) from the blood, we hypothesize that T cells may serve as integrators of risk factors for brain disorders, including gliomas. Current studies in the laboratory are focused on understanding how environmental exposures and systemic diseases impact on glioma formation and progression in mice(14, 15).

I want to thank the wonderful trainees whom I have had the pleasure of mentoring, and look forward to similarly exciting new breakthroughs from future members of our team. You can learn more by following us on Twitter.
David H. Gutmann, MD, PhD, FAAN

Dr. Xiaofan (Gary) Guo

Dr. Yuan Pan


1.   Campen CJ, Gutmann DH. Optic Pathway Gliomas in Neurofibromatosis Type 1. J Child Neurol 33, 73-81 (2018).
2.   Hegedus B, et al. Preclinical cancer therapy in a mouse model of neurofibromatosis-1 optic glioma. Cancer Res 68, 1520-1528 (2008).
3.   Daginakatte GC, Gianino SM, Zhao NW, Parsadanian AS, Gutmann DH. Increased c-Jun-NH2-kinase signaling in neurofibromatosis-1 heterozygous microglia drives microglia activation and promotes optic glioma proliferation. Cancer Res 68, 10358-10366 (2008).
4.   Daginakatte GC, Gutmann DH. Neurofibromatosis-1 (Nf1) heterozygous brain microglia elaborate paracrine factors that promote Nf1-deficient astrocyte and glioma growth. Hum Mol Genet 16, 1098-1112 (2007).
5.   Pong WW, Higer SB, Gianino SM, Emnett RJ, Gutmann DH. Reduced microglial CX3CR1 expression delays neurofibromatosis-1 glioma formation. Ann Neurol 73, 303-308 (2013).
6.   Toonen JA, Solga AC, Ma Y, Gutmann DH. Estrogen activation of microglia underlies the sexually dimorphic differences in Nf1 optic glioma-induced retinal pathology. J Exp Med 214, 17-25 (2017).
7.   Chen YH, et al. Mouse low-grade gliomas contain cancer stem cells with unique molecular and functional properties. Cell Rep 10, 1899-1912 (2015).
8.   Pan Y, et al. Athymic mice reveal a requirement for T-cell-microglia interactions in establishing a microenvironment supportive of Nf1 low-grade glioma growth. 32, 491-496 (2018).
9.   Guo X, Pan Y, Gutmann DH. Genetic and genomic alterations differentially dictate low-grade glioma growth through cancer stem cell-specific chemokine recruitment of T cells and microglia. Neuro Oncol,  21, 1250-1262 (2019).
10.  Guo X PY, Xiong M, Sanapala S, Anastasaki C, Cobb O, Dahiya S, Gutmann DH. Midkine activation of CD8+ cells establishes a neuron-immune-cancer axis responsible for low-grade glioma growth. Nat Commun In press, (2020).
11.  Solga AC, et al. RNA Sequencing of Tumor-Associated Microglia Reveals Ccl5 as a Stromal Chemokine Critical for Neurofibromatosis-1 Glioma Growth. Neoplasia 17, 776-788 (2015).
12.  Monje M, et al. Roadmap for the Emerging Field of Cancer Neuroscience. Cell 181, 219-222 (2020).
13.  Wright-Jin EC, Gutmann DH. Microglia as Dynamic Cellular Mediators of Brain Function. Trends Mol Med 25, 967-979 (2019).
14.  Johnson KJ, Zoellner NL, Gutmann DH. Peri-gestational risk factors for pediatric brain tumors in Neurofibromatosis Type 1. Cancer Epidemiol 42, 53-59 (2016).
15.  Porcelli B, Zoellner NL, Abadin SS, Gutmann DH, Johnson KJ. Associations between allergic conditions and pediatric brain tumors in Neurofibromatosis type 1. Fam Cancer 15, 301-308 (2016).

Human iPSC-Derived Neurons and Cerebral Organoids Establish Differential Effects of Germline NF1 Gene Mutations

Anastasaki C, Wegscheid M, et al., Stem Cell Reports 2020

Neurofibromatosis type 1 (NF1) is a common neurodevelopmental disorder caused by aspectrum of distinct germline NF1 gene mutations, traditionally viewed as equivalent loss-of-function alleles. To specifically address the issue of mutational equivalency in a disease with considerable clinical heterogeneity, we engineered seven isogenic human induced pluripotent stem cell lines, each with a different NF1 patient NF1 mutation, to identify potential differential effects of NF1 mutations on human central nervous system cells and tissues. Although all mutations increased proliferation and RAS activity in 2D neural progenitor cells (NPCs) and astrocytes, we observed striking differences between NF1 mutations on 2D NPC dopamine levels, and 3D NPC proliferation, apoptosis, and neuronal differentiation in developing cerebral organoids. Together, these findings demonstrate differential effects of NF1 gene mutations at the cellular and tissue levels, suggesting that the germline NF1 gene mutation is one factor that underlies clinical variability.

Corina Anastasaki, PhD

Michelle Wegscheid, MD, PhD Candidate